Paclitaxel/5-FU Promising in Metastatic Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

ROME, Italy-The combination of paclitaxel (Taxol), fluorouracil (5-FU), and leucovorin, with G-CSF support, in pretreated patients with advanced breast cancer had a good toxicity profile and an encouraging response rate in a study from the Regina Elena Cancer Institute, Rome.

ROME, Italy—The combination of paclitaxel (Taxol), fluorouracil (5-FU),and leucovorin, with G-CSF support, in pretreated patients with advancedbreast cancer had a good toxicity profile and an encouraging response ratein a study from the Regina Elena Cancer Institute, Rome.

In the poster presentation, Dr. E. Terzoli described 16 heavily pretreatedadvanced breast cancer patients who received paclitaxel, 135 to 175 mg/m²onday 1 and fluorouracil, 350 to 375 mg/m², plus leucovorin, 10 to 100mg/m², on days 1 to 3. The cycle was repeated every three weeks withG-CSF added to prevent neutropenia.

The combination therapy was delivered as first-line metastatic treatmentin three patients, second-line in five patients, and third-line or higherin eight patients. All patients had received previous anthracyclines, andeight had taken hormones.

Five of 10 evaluable patients had a partial response, and in four ofthese patients, the treatment represented third-line chemotherapy. Overall,the combination was well tolerated.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.